Condensed Consolidated Balance Sheets (USD $) In Thousands	Sep. 30, 2011		Dec. 31, 2010
Current assets:
Cash and cash equivalents	$ 542,545		$ 243,197
Marketable securities, available for sale	116,140		788,214
Restricted cash and cash equivalents (Alios)	50,580	[1]
Accounts receivable, net	445,661	[1]	12,529
Inventories	67,654
Prepaid expenses and other current assets	23,245	[1]	13,099
Total current assets	1,245,825		1,057,039
Restricted cash	34,119		34,090
Property and equipment, net	101,268	[1]	72,333
Intangible assets	663,500	[1]	518,700
Goodwill	33,501	[1]	26,102
Other assets	13,785	[1]	17,182
Total assets	2,091,998		1,725,446
Current liabilities:
Accounts payable	49,248	[1]	35,851
Accrued expenses and other current liabilities	229,865	[1]	134,414
Accrued interest	6,700		3,462
Deferred revenues, current portion	55,695		74,619
Accrued restructuring expense, current portion	5,108		5,497
Secured notes (due 2012)	98,416		136,991
Liability related to sale of future milestone payments	94,162		77,799
Income taxes payable (Alios)	9,755	[1]
Other obligations			6,150
Total current liabilities	548,949		474,783
Deferred revenues, excluding current portion	126,221		160,049
Accrued restructuring expense, excluding current portion	21,476		24,098
Convertible senior subordinated notes (due 2015)	400,000		400,000
Deferred tax liability	231,184	[1]	160,278
Construction financing obligation	25,474
Other liabilities	7,848	[1]	2,265
Total liabilities	1,361,152		1,221,473
Commitments and contingencies
Redeemable noncontrolling interest (Alios)	36,696	[1]
Shareholders' equity:
Preferred stock, $0.01 par value; 1,000,000 shares authorized; none issued and outstanding at September 30, 2011 and December 31, 2010
Common stock, $0.01 par value; 300,000,000 shares authorized at September 30, 2011 and December 31, 2010; 208,460,778 and 203,522,976 shares issued and outstanding at September 30, 2011 and December 31, 2010, respectively	2,065		2,016
Additional paid-in capital	4,152,106		3,947,433
Accumulated other comprehensive loss	(945)		(1,067)
Accumulated deficit	(3,573,464)		(3,444,409)
Total Vertex shareholders' equity	579,762		503,973
Noncontrolling interest (Alios)	114,388	[1]
Total shareholders' equity	694,150		503,973
Total liabilities and shareholders' equity	$ 2,091,998		$ 1,725,446

[1] Amounts include the assets and liabilities of Vertex's variable interest entity ("VIE"), Alios BioPharma, Inc. ("Alios"). Vertex's interests and obligations with respect to the VIE's assets and liabilities are limited to those accorded to Vertex in its agreement with Alios. See Note K to these condensed consolidated financial statements for amounts.